Evaluation of pantoprazol treatment response of patients with asthma and gastroesophageal reflux: a randomized prospective double-blind placebo-controlled study.
OBJECTIVE
To determine the effect that the treatment of GERD has on the clinical management, as well as the respiratory function, of patients with asthma and to evaluate the clinical characteristics of this group of patients.


METHODS
Patients with asthma and concomitant GERD, documented using 24 h pH-metry, were evaluated by means of quality of life questionnaires, as well as questionnaires related to respiratory and digestive symptoms. In addition, esophageal manometry, spirometry and the determination of peak expiratory flow were also performed prior to and after the study. Forty-nine individuals who were diagnosed with GERD by means of 24 h esophageal pH-metry were selected and participated in a clinical randomized double-blind placebo-controlled study, involving the administration of 40 mg/day of pantoprazol for 12 consecutive weeks.


RESULTS
Forty-four individuals completed the study (n = 22 per group). There was significant improvement in the scores for respiratory symptoms and quality of life only in the group that received pantoprazol (p = 0.01 and p = 0.001, respectively). No respiratory function parameters changed in either group.


CONCLUSIONS
In this study, the effective treatment of GERD improved patient quality of life, and the symptoms of asthma significantly decreased in the group that received the medication. There were no changes in pulmonary function parameters.
dos Santos
Leandro Heusi
LH
Federal University of Rio Grande do Sul, Porto Alegre, RS, Brasil.
Ribeiro
Iana Oliveira e Silva
IO
Sánchez
Pablo Gerardo
PG
Hetzel
Jorge Lima
JL
Felicetti
José Carlos
JC
Cardoso
Paulo Francisco Guerreiro
PF
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology* / Q000628:therapy; D004812:Epidemiologic Methods; D004947:Esophagus / Q000503:physiopathology; D005260:Female; D005541:Forced Expiratory Volume; D005745:Gastric Acidity Determination; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008365:Manometry; D008499:Medical Records; D008875:Middle Aged; D000077402:Pantoprazole; D010366:Peak Expiratory Flow Rate; D010919:Placebos; D011788:Quality of Life; D012129:Respiratory Function Tests; D013147:Spirometry / Q000379:methods; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D010919:Placebos; D000077402:Pantoprazole